BC Week In Review | Jul 28, 2017
Clinical News

Bayer's anetumab ravtansine misses in Phase II for mesothelioma

Bayer AG (Xetra:BAYN) reported data from a Phase II trial in 248 patients with malignant pleural mesothelioma (MPM) showing that second-line treatment with IV anetumab ravtansine (BAY 94-9343) every 3 weeks missed the primary endpoint...
BC Extra | Jul 21, 2017
Clinical News

Bayer's ADC fails in mesothelioma trial

Bayer AG (Xetra:BAYN) said antibody-drug conjugate anetumab ravtansine ( BAY 94-9343 ) missed the primary endpoint of progression-free survival (PFS) in a Phase II trial to treat malignant pleural mesothelioma (MPM) in a second-line setting. The study...
BioCentury | Jun 23, 2017
Emerging Company Profile

TRuCs vs. CARs

TCR2 Therapeutics Inc. is creating autologous T cell therapies that it thinks will have greater activity against solid tumors than CAR T therapies, and broader applicability than TCR therapies. The key to the approach is...
BC Week In Review | Jun 13, 2016
Clinical News

Anetumab ravtansine: Phase I data

Data from 147 evaluable patients with advanced solid tumors refractory to standard treatment in an open-label, dose-escalation, U.S. Phase I trial showed that the maximum tolerated dose (MTD) of IV anetumab ravtansine was 6.5 mg/kg...
BC Week In Review | Feb 1, 2016
Clinical News

Anetumab ravtansine: Phase II started

Bayer began an open-label, international Phase II trial to compare 6.5 mg/kg IV anetumab ravtansine every 3 weeks vs. IV vinorelbine once weekly in about 183 patients. The start triggered an undisclosed milestone payment to...
Items per page:
1 - 5 of 5